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Abstract
Research suggests that fibromyalgia is a central, widespread pain syndrome supported by a generalized disturbance
in central nervous system pain processing. Over the past decades, multiple lines of research have identified the
locus for many functional, chronic pain disorders to the central nervous system, and the brain. In recent years, brain
neuroimaging techniques have heralded a revolution in our understanding of chronic pain, as they have allowed
researchers to non-invasively (or minimally invasively) evaluate human patients suffering from various pain disorders.
While many neuroimaging techniques have been developed, growing interest in two specific imaging modalities
has led to significant contributions to chronic pain research. For instance, resting functional connectivity magnetic
resonance imaging (fcMRI) is a recent adaptation of fMRI that examines intrinsic brain connectivity - defined as
synchronous oscillations of the fMRI signal that occurs in the resting basal state. Proton magnetic resonance
spectroscopy (
1H-MRS) is a non-invasive magnetic resonance imaging technique that can quantify the concentration of
multiple metabolites within the human brain. This review will outline recent applications of the complementary
imaging techniques - fcMRI and
1H-MRS - to improve our understanding of fibromyalgia pathophysiology and how
pharmacological and non-pharmacological therapies contribute to analgesia in these patients. A better understanding
of the brain in chronic pain, with specific linkage as to which neural processes relate to spontaneous pain perception
and hyperalgesia, will greatly improve our ability to develop novel therapeutics. Neuroimaging will play a growing role
in the translational research approaches needed to make this a reality.
Fibromyalgia: a centralized pain disorder
Fibromyalgia (FM) is the second most common rheuma-
tologic disorder, behind osteoarthritis, with 2 to 4% of the
populations of industrialized countries affected [1]. Over-
all, it is estimated that FM costs American taxpayers over
$20 billion a year in lost wages and disability [2]. In part,
this burden on the US health care system stems from our
lack of understanding of the specific pathophysiology of
the disorder. Research suggests that FM is a central wide-
spread pain syndrome [3,4]; however, it is uncertain if the
observed neurobiological outcomes are causally related to
development of this condition. That said, emerging data
suggest a generalized disturbance in central nervous sys-
tem pain processing, which leads individuals to sense pain
throughout the body in the absence of inflammatory or
patho-anatomic damage [5].
Neuroimaging and pain: multiple windows into
brain chemistry and function
Over the past decades, multiple lines of research have iden-
tified the locus for many functional, chronic pain disorders
as the central nervous system, and the brain. Abnormal
brain processing includes sensitization supported by aber-
rant inter-regional communication and other alterations in
both structure and function, including neurotransmitter
levels, all of which may ultimately maintain the chronic
pain state. Brain neuroimaging techniques have heralded a
revolution in our understanding of chronic pain, as they
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invasively) evaluate human patients suffering from various
pain disorders.
Resting functional connectivity magnetic resonance im-
aging (fcMRI) is a recent adaptation of fMRI that examines
intrinsic connectivity - defined as synchronous oscillations
of the fMRI signal that occurs in the resting basal state. In-
trinsic brain connectivity may be important for mainten-
ance of synaptic connectivity and, as such, modulates the
efficiency and extent of neuronal transmission between
brain regions. Intrinsic connectivity, as measured by neuro-
imaging methods, follows known structural monosynaptic
and polysynaptic pathways [6], likely reflecting meaningful
neurophysiological activity [7] within known primary sen-
s o r y ,e x e c u t i v e ,a n da s s o c i a t i v en e t w o r k s[ 8 ] .
In simple terms, the subject is instructed to lie still in-
side the scanner and limit head motion. Analyses aim to
understand patterns in the spontaneous fluctuations in
the blood oxygenation level-dependent (BOLD) signal
over time [9]. For instance, neural communication be-
tween distant brain regions is thought to be reflected by
a significant correlation between fMRI signal time series
from those regions. Thus, this technique is particularly
sensitive to the investigation of brain networks, or
co-activated assemblies of brain areas, and stable, repro-
ducible networks processing both primary sensory and
associative, and higher cognitive functions [10].
The spontaneous fluctuations in the resting fMRI sig-
nal demonstrate peak power at low frequencies (approxi-
mately 0.01 to 0.05 Hz). Thus, it is important to keep in
mind that many of the correlations reported characterize
neural fluctuations that occur over tens of seconds.
Moreover, resting fcMRI analyses do not typically evalu-
ate causal relationships between brain regions. Such ana-
lyses are suspect due to the fact that the hemodynamic
response function (which converts neuronal activity to
BOLD hemodynamic response) varies across the brain.
Hence, preceding activation in one brain area compared
to a second brain area may reflect true causal influence
or, alternatively, a hemodynamic response function that
peaks earlier in time compared to the second area [11].
Multiple techniques have been devised to evaluate func-
tional brain connectivity. For correlational analyses, the
main techniques are seed correlation and independent
component analysis (ICA). For seed correlation, the fMRI
signal is extracted from a seed region of interest, and is
then correlated with the fMRI time series taken from all
other brain voxels [12]. Alternatively, ICA is a data-driven
technique that considers all voxels in the brain and clus-
ters them into spatiotemporally distinct networks, which
are spatially independent of one another [13].
Different fcMRI techniques have been applied to better
understand brain processing related to pain. The applica-
tion to chronic pain has been an important development,
as clinical pain is much more difficult to study com-
pared to evoked, or experimental, pain. Chronic pain
manifests in spontaneous fluctuations of clinical pain.
Such fluctuations shift connectivity between different
brain regions and networks, a phenomenon that can be
tracked with fcMRI.
A complementary neuroimaging technique to fcMRI is
proton magnetic resonance spectroscopy (
1H-MRS). This
method is a non-invasive MRI technique that can quantify
the concentration of multiple metabolites within the hu-
man brain. Of significance to the field of chronic pain, this
method can be used to identify static as well as changing
levels of specific brain neurotransmitters involved in pain
processing and modulation. In this respect,
1H-MRS is
complementary to fcMRI as it allows for the determin-
ation of the concentrations of specific neurotransmitters
and brain metabolites involved in neural signaling that
likely relate to the fcMRI signal. This technique generates
a specific chemical spectrum, rather than a functional
brain map, by exciting protons with characteristic reson-
ance frequencies [14]. Once
1H-MRS spectra are acquired,
they are analyzed offline to determine the relative concen-
trations of different metabolites [15]. This technique uses
the same MRI scanner used to generate fcMRI data, and
since
1H-MRS can be performed in the same scanning
session, resting levels of brain metabolites and brain con-
nectivity maps can be acquired with minimal time lag be-
tween acquisitions. Although the metabolites with the
largest signal-to-noise ratios in
1H-MRS are N-acetyl-
aspartate (NAA), choline (Cho), and creatine, recent in-
vestigations have targeted the brain’s main excitatory and
inhibitory neurotransmitters - glutamate and gamma-
amino-butyric acid (GABA), respectively. Emerging data
suggest that these molecules may be key factors in how
sensitized a given area of the cortex is to stimuli, and this
in turn may be related to brain connectivity.
1H-MRS in fibromyalgia and other pain states
Alterations in the levels of multiple metabolites have been
associated with various pain conditions thought to have
underlying brain dysfunction. NAA is a metabolite that
has historically been believed to be a marker of neuronal
density and viability, and lower concentrations of this mol-
ecule are thought to be indicative of loss of neural func-
tion and activity [16,17]. Cho is also involved in neural
activity as it plays a role in membrane integrity [16]. Creat-
ine is a molecule that is involved in cellular energy and it
plays a role in ATP metabolism and production. Since this
molecule displays relatively stable levels across brain re-
gions, it is sometimes used as a reference metabolite to
which other molecules are normalized.
Over the past decade, the application of
1H-MRS
methods to the investigation of chronic pain has gained
popularity. Grachev and Apkarian [18] were the first to
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cortex (DLPFC) of individuals with chronic low back pain
compared with healthy controls. Subsequent reports of
lower brain NAA levels have also been found in other
chronic pain conditions, including neuropathic pain [19],
trigeminal neuralgia [20], and headache/migraine [21,22].
This finding of lower NAA within the brain extends to pa-
tients with ‘centralized’ pain such as FM. Four independ-
ent trials have reported reductions in hippocampal NAA
levels within individuals with FM [23-26]. In fact, Wood
and colleagues [26] reported that reduced NAA within the
hippocampus was also associated with greater symptom
burden, as assessed by the Fibromyalgia Impact Question-
naire. These findings of lower NAA in the FM hippocam-
pus are robust and likely reflect a true finding as a recent
1H-MRS meta-analysis of these same four trials, including
58 patients with FM and 38 pain free controls, showed a
statistical reduction in hippocampal NAA in FM [27].
Although reduced NAA levels may be a common chem-
ical alteration in chronic pain, there needs to be caution in
the interpretation of this finding. The causal relationship
between hippocampal NAA and pain has yet to be dem-
onstrated. It is not known if lower NAA promotes the de-
velopment of chronic pain, if chronic pain drives the
reduction in NAA, or if both occur simultaneously. Lower
hippocampal NAA may also simply be a marker for
chronic pain and not be in the causal pathway. To resolve
these questions, longitudinal studies that follow patients
as they develop pain symptoms are needed.
Differences in other metabolite levels have also been
found in centralized pain states. Our group found an asso-
ciation between Cho levels within the DLPFC and spon-
taneous clinical pain: greater Cho levels were positively
correlated with self-reported chronic pain [28]. Emad and
colleagues [25] reported elevations in Cho within the right
hippocampus; however, the two trials by Fayed and col-
leagues [23,24] found reductions in Cho within the left
hippocampus, while no differences in hippocampal Cho
were found by Wood and colleagues [26].
While the molecular constituents of chronic centralized
pain may involve NAA, and to some degree Cho, a model
of how these metabolites play a role in pain presentation
is lacking. In an effort to explore more traditional neural
markers, recent work has begun to explore the role of
brain glutamate and glutamine in centralized pain pa-
tients. As mentioned above, glutamate is the brain’s main
excitatory neurotransmitter and it exerts its effects via
binding to both ionotropic and metabotropic receptors.
Ionotropic receptors are ligand-gated ion channels gener-
ally involved in fast synaptic transmission, which open up
permeation pathways through the plasma membrane,
allowing for fast changes in membrane potentials. Metab-
otropic receptors are G-protein-coupled receptors that
typically signal through cytoplasmic second messengers
and are more involved in modulation of neural activity.
The role of glutamatergic neurotransmission in pain has
been known for some time. For example, the development
of neuropathic pain in preclinical models is thought to be,
in part, a result of central sensitization, or central plasti-
city, involving both ionotropic as well as metabotropic glu-
tamate receptors (reviewed in [29]). It remains to be seen
if these processes are also involved in the brains of chronic
pain patients that go on to develop centralized pain.
Our group was the first to use
1H-MRS to study glutam-
ate and Glx (combined glutamate and glutamine) levels
specifically in patients with chronic ‘centralized’ pain. In a
longitudinal trial of acupuncture and sham acupuncture,
we demonstrated that changes in Glx levels, specifically
within the posterior insula cortex, tracked with changes in
both experimental and clinical pain [30]; greater reduc-
tions in Glx were associated with greater improvements in
both clinical and experimental pain. An important aspect
of this study was that the changes in insular Glx were also
associated with concomitant changes in the brain’sf u n c -
tional response to evoked pressure pain. This suggested
the possibility that brain Glx levels may actually be associ-
ated with neural activity, and not simply a marker of pain.
Similar findings have been found in other trials assessing
the relationship between
1H-MRS-derived neurotransmitter
levels and fMRI response [31]. Subsequently, our group
compared glutamate and Glx levels within the posterior in-
sula between FM patients and pain-free controls and found
significantly elevated levels of these molecules in the FM
patients. In both the FM and pain-free groups, however, the
degree of Glx elevation was associated with evoked pain
sensitivity, suggesting that glutamatergic activity in this re-
gion of the brain might be responsible, in part, for the ‘gain
setting’ on central neural pain processing [32].
Findings of elevated Glx within the FM brain have also
been reported by other groups, albeit focusing on different
brain regions. Elevations in the levels of Glx have been re-
ported in the amygdala [33], the posterior cingulate [34],
and the ventral lateral prefrontal cortex [35] of individuals
with FM. The emerging view is that there may be multiple
loci within the FM brain wherein elevated Glx may play
ar o l ei nc h r o n i cp a i ns y m p t o m s .T h i si si na g r e e m e n t
w i t ht h ef a c tt h a tm a n yo ft h e s ep a t i e n t sc o m p l a i no f
symptoms, in addition to pain, that also have brain-
based neurobiological underpinnings, namely mood dis-
turbance, poor sleep, cognitive dysfunction, and fatigue.
However, there does not appear to be global or ‘non-
specific’ elevations in brain Glx as these findings have
not been detected in every region examined. No eleva-
tions have been detected in the anterior insula [32] or
the prefrontal cortex [33].
These findings could represent more glutamate within
synaptic vesicles, higher numbers or densities of gluta-
matergic synapses, or even less reuptake of glutamate
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could enhance excitatory neurotransmission and subse-
quent pain. In neuropathic pain, plastic changes occurring
in the spinal cord and brain are thought to result from
some of these mechanisms. These changes in brain Glx in
centralized pain may also reflect processes similar to cen-
tral sensitization that have been reported in animal models
[29] and have been proposed in FM [36].
However, some limitations need to be acknowledged
before we can make these conclusions. First,
1H-MRS-
derived levels of glutamate are not purely estimates of
glutamate. As mentioned above, glutamine has mag-
netic resonances that overlap glutamate [14], thus pre-
cluding the ability to assign altered levels solely to
glutamate. Second, glutamate is not solely a neurotrans-
mitter. Within the brain, glutamate is involved in the
citric acid cycle and synthesis of ATP, glutamate levels
thus reflecting not only neurotransmission but also me-
tabolism. Finally,
1H-MRS voxels contain multiple cell
types. The Glx levels detected with
1H-MRS are present
not only in the neurons themselves, but also glia and
other cell types within the brain. The cellular compart-
ment from where the elevated glutamate signal origi-
nates in FM is not known, and changes in glutamate
and Glx observed in FM may be at regions remote from
the synapse.
While interpretation of
1H-MRS levels of glutamate
are somewhat problematic, the assessment of the brain’s
major inhibitory neurotransmitter, GABA, may be eas-
ier. Unlike glutamate and Glx, GABA does not play a
role in metabolism and, as such,
1H-MRS-derived
GABA levels may be more indicative of neural activity.
Interestingly, recent results suggest that decreased fMRI
BOLD signals are associated with higher GABA levels
[37], although other processes may be operative as the
fMRI BOLD signal involves non-neuronal factors (that
is, the hemodynamic response).
Similar to glutamate, GABA binds to both ionotropic
as well as metabotropic receptors; however, unlike glu-
tamate the binding of GABA typically leads to neuronal
inhibition through the opening of an electric shunt with
the neuronal membrane potential. GABA receptors are
widely distributed throughout the brain and spinal cord
where they are thought to modulate pain processing.
The first studies showing that GABA plays a critical role
in pain transmission involved demonstrating that baclo-
fen, a GABA-B receptor agonist, blocked pain in preclin-
ical models of acute and chronic pain [38]. These effects
were likely mediated by both spinal and supraspinal
GABA-B receptors. Interestingly, decreases in insular
GABA levels exacerbate pain whereas blocking GABA
degradation, within this structure, relieves pain [39].
These results suggest that GABA may play a role in the
pathophysiology of some chronic pain states.
We were the first to report that GABA levels are al-
tered within the centralized pain brain [40]. Although
this was a pilot study, within a sample of 16 FM patients
and 17 age- and sex-matched healthy controls, we found
lower GABA levels specifically within the anterior insula.
No reductions were detected within the posterior insula;
however, lower GABA levels within the posterior insula
were associated with greater sensitivity to experimental
pain. These findings suggested that lower insular GABA
may also play a role in pain, namely neuronal disinhib-
ition. Our results also raise the intriguing possibility of a
neurotransmitter imbalance within the insula of FM pa-
tients. There may be an elevation in the ratio of insular
Glx/GABA (excitatory/inhibitory) in centralized pain.
fcMRI in fibromyalgia
fcMRI is a technique for analysis of the resting state
BOLD time series; that is, when no experimental task is
imposed on the subject. Studies applying fcMRI tech-
niques to FM complement evoked pain fMRI studies, as
the latter mainly interrogate hyperalgesia and allodynia
phenomena in FM patients, but do not evaluate the
brain correlates of spontaneous clinical pain in these pa-
tients. Napadow and colleagues evaluated resting, or in-
trinsic, brain connectivity in FM patients using ICA [41].
They found altered connectivity between the insula and
the default mode network (DMN) and the executive at-
tention network (EAN; also known as the frontoparietal
control network). The DMN [8,9] is a constellation of
brain regions thought to be engaged in self-referential
cognition, which are ‘deactivated’ during various exter-
nally focused task conditions. The DMN includes the in-
ferior parietal lobule, the posterior cingulate cortex
(PCC) and precuneus, medial prefrontal cortex (mPFC),
the hippocampal formation, and the lateral temporal
cortex [42]. Pain is known to influence both DMN re-
sponse and cognitive capacity. While acute experimental
pain induces DMN deactivation in healthy subjects [43],
chronic back pain is associated with mitigated DMN de-
activation to visual attention tasks [44]. The EAN com-
prises the dorsolateral prefrontal and posterior parietal
cortices and is involved in executive control over behav-
ior. The DMN showed greater connectivity to the insula
cortex and secondary somatosensory cortex (S2) (brain
regions known to process evoked experimental pain and
somatosensation), while the EAN showed greater intra-
network connectivity in FM patients. The medial visual
network, which was used as a control, did not show
functional differences between patients and controls.
Moreover, both the DMN and EAN were more con-
nected to the insula in patients reporting greater spon-
taneous clinical pain at the time of the scan. This
suggested a close link between DMN-insula connectivity
and clinical pain.
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system and increased connectivity between the DMN and
somatosensory processing regions such as S2 (as also
mentioned above) were recently reported by Pujol and
colleagues [45]. Such independent, confirmatory data are
important for any neuroimaging-based markers of disease
in FM, and further research is needed. Interestingly, this
study also found altered connectivity with brain regions
supporting visual and auditory processing, which may re-
late to the multi-sensory dysfunction sometimes reported
in these patients.
In a different study, Cifre and colleagues [46] used a
seed voxel region of interest approach and showed a pat-
tern of both increased and decreased brain connectivity
in FM patients. Increased connectivity was found be-
tween DMN areas such as mPFC and PCC and also be-
tween anterior cingulate cortex and the insula. These
results support the fact that DMN and insula resting
connectivity is disrupted in FM. Some results may also
extend to other pain conditions, as Kucyi and colleagues
[47] also found increased mPFC to PCC connectivity in
patients with temporomandibular disorder, with greater
mPFC-PCC connectivity associated with greater rumin-
ation about pain reported by the patients.
Ceko and colleagues [48] explored structural and
fMRI changes in FM patients, and found an interesting
association with age. Younger, but not older, FM pa-
tients showed decoupling between the insula and anter-
ior mid-cingulate cortex, two brain regions that are
normally strongly connected in healthy adults, as part
of a salience network.
In addition to altered connectivity, potential spectral
power differences have also been explored in resting fcMRI
data. Kim and colleagues [49] reported increased frequency
power (for a broad 0.01 to 0.25 Hz band) in somatosensory
(primary somatosensory cortex, S1), cognitive (DLPFC) and
affective (amygdala) brain regions in FM patients.
Relationship between the functional and chemical
imaging findings and pain
It is becoming increasingly apparent that altered connect-
ivity and neurochemistry are present within the FM brain.
However, it is currently unknown if these processes are
operative in the same brain regions and within the same
individuals. No group to date has explored the relationship
between
1H-MRS-derived neurotransmitter levels and
functional connectivity in a chronic pain cohort. Recent
work has investigated the relationship between Glx- and
GABA-derived spectroscopy values within the posterior
cingulate and connectivity of this structure to the rest of
the DMN [50]. The authors find that individuals with
greater concentrations of Glx and lower concentrations of
GABA within the posterior cingulate have stronger con-
nectivity values with other DMN regions. One approach
that may be particularly informative in FM would be to
explore the association between insula connectivity and
Glx/GABA levels in the same patient cohort. For instance,
a connectivity seed voxel could be placed within the insula
that matches the
1H-MRS voxel in position and shape,
and analyses could determine if Glx within the insula is re-
lated to connectivity of this structure with the rest of the
brain (see below). This type of multi-modal imaging would
be particularly informative and may provide synergistic in-
sights into central neurobiological pathways that are dys-
regulated in chronic pain. Alternatively, Glx and GABA
concentration in the insula may also influence functional
connectivity between other brain regions and networks, as
the insula has widely distributed excitatory and inhibitory
connections throughout the brain.
Neuroimaging of treatment effects
Neuroimaging techniques have been applied to further
our understanding of the brain mechanisms supporting
pharmacological and non-pharmacological analgesic ther-
apies for FM. For instance, Napadow and colleagues [51]
demonstrated that DMN-insula connectivity, which was
increased in FM patients, was reduced following 4 weeks
of non-pharmacological acupuncture and sham acupunc-
ture therapy, which reduced pain in these patients. The
authors suggested that connectivity between the DMN
and insula may serve as a possible surrogate biomarker for
pain reduction in FM.
Recently, pregabalin, a pharmacologic intervention ap-
proved by the United States Food and Drug Administra-
tion for the treatment of FM, has been investigated in a
multi-modal MRI study [52]. Consistent with the preclin-
ical mechanism of action of this compound (that is, a re-
duction in the release of glutamate into the synapse),
Harris and Napadow and colleagues found that pregabalin
reduced Glx levels in the posterior insula [52]. Moreover
higher pre-treatment levels of Glx were associated with
greater subsequent reductions in sensitivity to experimen-
tal pressure pain. Patients that had greater reductions in
clinical pain also displayed greater concomitant reductions
in functional connectivity between the posterior insula
and DMN structures, consistent with earlier reports link-
ing DMN-insula connectivity with spontaneous fluctua-
tions in clinical pain.
Where future studies are needed
While studies to date have made tremendous progress
in delineating the brain mechanisms supporting persist-
ent pain in FM patients, future studies will need to bet-
t e rl i n kn e u r o p l a s t i cc h a n g ei nt h eb r a i nw i t hb o t hp a i n
and non-pain clinically relevant outcomes. As FM is a
multi-dimensional disorder, non-pain outcomes (such
as fatigue, cognitive deficits, mood disturbance, and
poor sleep) should also be explored with brain imaging
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involves altered central nervous system physiology is
much needed to understand how different symptoms
co-occur in FM patients. Future studies will need to ac-
curately phenotype FM patients to determine the rela-
tive levels of these comorbid symptoms in order to
ascertain which brain outcomes are related to specific
clinical outcomes. Given the emerging belief that FM
m a yb ea nu m b r e l l ad i a g n o s i sf o rm u l t i p l ed i f f e r e n ts u b -
types of patients suffering from whole-body pain, differ-
ences in brain alterations between different patient
subgroups may help explain symptom heterogeneity.
Finally, several potential confounds inherent to the
previously described neuroimaging markers need to be
mentioned. Firstly, cardiorespiratory artifacts and subject
motion inside the MRI scanner can significantly affect
the neuroimaging markers noted above. For instance,
head motion has been shown to reduce spectral power
at low frequencies and increase power at high frequen-
cies (likely due to the jerky nature of such motion). Im-
portantly, these motion-related effects are greater in
association networks such as the DMN and fronto-
parietal control network [53]. As patients tend to move
more than healthy control subjects, these effects need to
be disentangled from real neuroplastic changes. At the
least, head motion should be quantified and reported.
Furthermore, physiological monitoring should be used
in resting connectivity analyses, in order to remove, or
mitigate, cardiorespiratory artifacts in the data. From a
clinical perspective, many FM patients take medications
that could alter brain outcomes, potentially making it diffi-
cult to assign altered brain outcomes to the presence of
the disorder as opposed to the confounding effects of cer-
tain drugs. Finally, most neuroimaging studies are per-
formed on relatively small sample sizes; for example, it is
not uncommon for a neuroimaging trial to enroll fewer
than 30 patients. While small sample sizes may still pro-
vide sufficient power for neuroimaging outcomes, it
does limit our ability to generalize any one finding into
the larger population of centralized pain patients. One
w a ya r o u n dt h i sp r o b l e mi st h eg e n e r a t i o no fs h a r e d
data across institutions as in the large NIH-funded
Multidisciplinary Approach to the Study of Chronic Pel-
vic Pain (MAPP) initiative, which is focused on the
characterization of patients suffering from pelvic pain.
In the future, these types of ‘big data’ approaches will be
needed to help us better understand centralized pain
disorders and other related syndromes.
Conclusion
fcMRI and
1H-MRS analyses have identified significant al-
terations in brain function and neurotransmitter concen-
tration in the FM brain. While these analysis approaches
are relatively new and still evolving, future studies with
greater power will better link these brain changes with
clinically relevant outcome metrics. Such research will
lead to an improved understanding of how brain changes
reflect and even maintain persistent pain in FM.
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